奥克列珠单抗
美罗华
医学
多发性硬化
奥图穆马
临床试验
CD20
单克隆抗体
单克隆
免疫学
芬戈莫德
内科学
肿瘤科
抗体
作者
Luciana Midaglia,Lidia Mora,Patricia Mulero,Jaume Sastre‐Garriga,Xavier Montalbán
出处
期刊:PubMed
[National Institutes of Health]
日期:2018-01-01
卷期号:66 (1): 25-32
被引量:7
摘要
In all of the studies reviewed, rituximab demonstrated a consistent benefit in controlling inflammatory activity, both clinically, reducing the incidence of relapses, and radiologically, avoiding the appearance of new and/or active lesions. On the contrary, with regards to the progression of disability, its effect is more controversial. Safety profile appears acceptable. Rituximab seems to be an effective and safe drug in the treatment of MS.
科研通智能强力驱动
Strongly Powered by AbleSci AI